DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052100 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von César Fernández-de-Las-Peñas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain. Hauptthemen laut MEDLINE: DNA Methylation, Angiotensin-Converting Enzyme 2, COVID-19, Serine Endopeptidases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Comunidad de Madrid, Fondo Europeo De Desarrollo Regional.
Abstract (Originalsprache)
Genetics and epigenetics are mechanisms proposed for explaining post-COVID-19 condition. This secondary analysis aimed to investigate if DNA methylation levels of the ACE2 promoter are different depending on the genotype of five COVID-19-related polymorphisms in individuals who had been previously hospitalized due to SARS-CoV-2 infection. We collected non-stimulated saliva samples from 279 (48.7% female, age: 56.0 ± 12.5 years) previously hospitalized COVID-19 survivors. The participants self-reported for the presence of post-COVID symptomatology that started after the infection and persisted at the time of the appointment. Three potential genotypes of ACE2 rs2285666 and rs2074192, TMPRSS2 rs12329760 and rs2070788, and ACE1 rs1799752 polymorphisms were identified from saliva samples. Further, methylation levels at five different locations (CpG) of dinucleotides in the ACE2 promoter were quantified using bisulfited pyrosequencing. Differences in the methylation percentage (%) of each CpG according to the genotype of the five polymorphisms were analyzed. Participants were evaluated up to 17.8 (SD: 5.2) months after hospital discharge. Eighty-eight percent (88.1%) of patients reported at least one post-COVID symptom (mean number of post-COVID symptoms: 3.0; SD: 1.9). Overall, we did not observe significant differences in the methylation levels of the ACE2 promoter according to the genotype of ACE2 rs2285666 and rs2074192, TMPRSS2 rs12329760 and rs2070788, or ACE1 rs1799752 single nucleoid polymorphisms. This study did not find an association between genetics (genotypes of five COVID-19-associated polymorphisms) and epigenetics (methylation levels of the ACE2 promoter) in a cohort of COVID-19 survivors with post-COVID-19 condition who were hospitalized during the first wave of the pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain.
- Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI) Center, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.
- Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos, 28933 Madrid, Spain.
- Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.
- Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), ISCIIII, 28040 Madrid, Spain.
ORCID-Profile: César Fernández-de-Las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, Stella M Gómez-Sánchez, Silvia Ambite-Quesada, Juan Torres-Macho, Pablo Ryan-Murua, Ana I Franco-Moreno, Oscar J Pellicer-Valero, Lars Arendt-Nielsen, Rocco Giordano
Förderung
- Novo Nordisk Foundation
- Comunidad de Madrid
- Fondo Europeo De Desarrollo Regional
Zitieren
APA
Fernández-de-Las-Peñas, C., Díaz-Gil, G., Gil-Crujera, A., Gómez-Sánchez, S. M., Ambite-Quesada, S., Torres-Macho, J., Ryan-Murua, P., Franco-Moreno, A. I., Pellicer-Valero, O. J., Arendt-Nielsen, L., & Giordano, R. (2025). DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052100
Vancouver
Fernández-de-Las-Peñas C, Díaz-Gil G, Gil-Crujera A, Gómez-Sánchez SM, Ambite-Quesada S, Torres-Macho J, et al. DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052100
BibTeX
@article{FernndezdeLasPeas2025,
author = {Fernández-de-Las-Peñas, César and Díaz-Gil, Gema and Gil-Crujera, Antonio and Gómez-Sánchez, Stella M and Ambite-Quesada, Silvia and Torres-Macho, Juan and Ryan-Murua, Pablo and Franco-Moreno, Ana I and Pellicer-Valero, Oscar J and Arendt-Nielsen, Lars and Giordano, Rocco},
title = {DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052100}
}
EUVIMED